Moolec Science (MLEC) Current Deferred Revenue (2024 - 2025)
Moolec Science (MLEC) reported Current Deferred Revenue of $1260.0 for Q2 2025, down 99.97% on a YoY basis from $3.9 million in Q2 2024, and down 99.97% sequentially from $3.9 million in Q2 2024.
Moolec Science (MLEC) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Moolec Science (MLEC) has 2 years of Current Deferred Revenue data on file, last reported at $1260.0 in Q2 2025.
- For the quarter ending Q2 2025, Current Deferred Revenue fell 99.97% year-over-year to $1260.0; the trailing twelve-month figure through Jun 2025 stood at $1260.0 (down 99.97% YoY), and the FY2025 full-year result was $1260.0, down 99.97% from the prior year.
- Current Deferred Revenue slipped to $1260.0 in Q2 2025, from $3.9 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $3.9 million in Q2 2024 to a low of $1260.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,260.00 |
| Jun 30, 2024 | 3.92 Mn |